| 0.4494 0.04 (9.85%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.73 | 1-year : | 0.91 |
| Resists | First : | 0.62 | Second : | 0.77 |
| Pivot price | 0.49  |
|||
| Supports | First : | 0.37 | Second : | 0.31 |
| MAs | MA(5) : | 0.42 |
MA(20) : | 0.52 |
| MA(100) : | 0.84 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13 |
D(3) : | 6.5 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 1.91 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TVGN ] has closed above bottom band by 34.7%. Bollinger Bands are 53.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.46 - 0.46 | 0.46 - 0.46 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.45 - 0.45 | 0.45 - 0.45 |
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Fri, 14 Nov 2025
Tevogen Bio Holdings Inc. Reports Reduced Operating Losses and Continued Growth in Quarterly Financial Results - Quiver Quantitative
Fri, 14 Nov 2025
Tevogen Bio Holdings Inc. SEC 10-Q Report - TradingView
Mon, 03 Nov 2025
Tevogen (NASDAQ: TVGN) raised - Stock Titan
Mon, 03 Nov 2025
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn - Sahm
Wed, 29 Oct 2025
Tevogen Bio (Nasdaq: TVGN) moves PredicTcell AI to beta; TVGN 489 at $9–$11B - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 197 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 79.3 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 2,230 (K) |
| Shares Short P.Month | 2,170 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -439.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -2.37 |
| PEG Ratio | 0 |
| Price to Book value | -5.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|